Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05891769 · ClinicalTrials.gov registry record · Phase 2
99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT
A Phase 2 study of Parathyroid Adenoma, sponsored by Andrei Iagaru.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT05891769: Recruiting Phase 2 study of Parathyroid Adenoma, sponsored by Andrei Iagaru.
NCT05891769 is a Phase 2 study of Parathyroid Adenoma that is actively recruiting participants, run by Andrei Iagaru. The registered enrollment target is 100 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05891769, a Phase 2 study of Parathyroid Adenoma, is actively recruiting participants, sponsored by Andrei Iagaru.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study proposes the use of a well-established PET isotope, Fluorine-18 (18F), bound to Choline, for a prospective single-center, single-arm study for participants with suspected parathyroid adenoma and negative or equivocal standard of care 99mTc Sestamibi SPECT/CT
Primary Outcome
Inclusion criteria suggest recruiting patients with negative or equivocal SPECT/CT, so based on this there will be 0 lesions on SPECT/CT. The goal is to compare/count the number of lesions from PET/CT, if any present versus no lesions with SPECT/CT
Conditions Studied
Interventions
- DRUG 18Fluorocholine
Study Locations (1)
California
- Stanford Hospital and Clinics - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-09-27 |
| Est. Completion | 2027-07-01 |
| Phase | Phase 2 |
What NCT05891769 shows while recruiting
NCT05891769 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower).
The record links to 1 condition, with Parathyroid Adenoma appearing as the primary indexed condition, and to 1 intervention - of which 18Fluorocholine is the first listed.
NCT05891769 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05891769 about?
NCT05891769 is a clinical study titled "99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT". This study proposes the use of a well-established PET isotope, Fluorine-18 (18F), bound to Choline, for a prospective single-center, single-arm study for participants with suspected parathyroid adenoma and negative or equivocal standard of care 99mTc Sestamibi SPECT/CT
What is the current status of trial NCT05891769?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2023-09-27. Estimated completion is 2027-07-01.
What conditions does trial NCT05891769 study?
This clinical trial studies the following conditions: Parathyroid Adenoma.
What interventions are being tested in trial NCT05891769?
The interventions under investigation include: 18Fluorocholine (DRUG).
Who is sponsoring clinical trial NCT05891769?
This trial is sponsored by Andrei Iagaru, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05891769 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05891769's enrollment target sits among peer trials
100 672nd of 2000 higher than 1,264 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI